West Deptford, NJ (PRWEB) January 29, 2014
Enclara Pharmacia, a leading hospice pharmacy provider, has just concluded another spectacular year of growth by adding over 5,200 patients and 52 new customers to its national service footprint in 2013. In addition, with a focus towards continued innovation, growth and scale, Enclara made some executive leadership enhancements during the second half of the year.
Andy Horowitz, CEO, and Founder states, “We truly appreciate the confidence that our new clients have placed with us and are very proud to be a leading choice for hospice pharmacy services. Even though we are excited about our continued success, our sights are still focused on delivering exceptional value – the highest level of clinical guidance and support in medication management in the most cost effective manner. We are driven to improve the customer experience, ensuring that our very first hospice client continues to realize the same attention to timely, quality-driven patient service, while our new customers feel the attention to detail and personal, executive touch that was lacking with their previous vendor.”
The company recently added Scott Baach, as Chief Administrative Officer / General Counsel; Rushi Patel, as Chief Operating Officer, and promoted Betsy Rothley to Chief Development Officer, overseeing both Sales, as well as Account Management. These enhancements brought clarity and direction to an already robust customer acquisition/retention platform.
Enclara understands the changing reimbursement climate that the hospice industry will soon be facing. In order to maneuver through these turbulent times, the Company has positioned itself as the only provider capable of offering a full-scale comprehensive mail order model, a PBM supported local retail pharmacy model with a suite of “ala carte” comprehensive clinical services, or the “hybrid” model, offering a combination of comprehensive clinical services or the economical PBM adjudicating platform dependent on patient need.
“2014 will pose new challenges to our hospice clients related to regulatory changes and potentially a more expanded interpretation of what medications are considered “related” to the terminal illness. Enclara is uniquely positioned to address these challenges and bringing solutions to our customers to allow them to manage in this new paradigm,” states Horowitz. “Managing drug costs while maintaining positive clinical outcomes, will only serve as a springboard to continued growth for Enclara. It’s how we built our business, we’re positioned to be the leader in this industry as hospice clients continue to look to us for solutions.”
About Enclara Pharmacia
Enclara Pharmacia supports their hospice partners through cost effective, clinical excellence in both mail order and local pharmacy access. Enclara, established in 2007, is committed to meeting the unique and changing needs of the hospice market and truly demonstrate that there is a difference in hospice pharmacy providers.